MedTrace Logo

A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma

NCT04624178 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-11-20

No results posted yet for this study

Summary

The purpose of this study is to find out whether combining the study drugs rucaparib and nivolumab may be an effective treatment for advanced and/or metastatic LMS, and whether the study treatment works as well as the standard chemotherapy for this type of cancer.

Conditions

  • Leiomyosarcoma

Interventions

DRUG

Rucaparib

Rucaparib at 600 mg, orally, twice daily, continuously for 28 days.

DRUG

Nivolumab

Nivolumab 480mg intravenously on day 1 of every four-week cycle.

Sponsors & Collaborators

Principal Investigators

  • Sujana Movva, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-05
Primary Completion
2026-11-16
Completion
2026-11-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04624178 on ClinicalTrials.gov